BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test
Are you concerned about chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL)? The BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test offered by DNA Labs UAE can provide valuable insights into your condition. Read on to learn more about this test, its cost, symptoms, diagnosis, and other important details.
Test Name: BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test
Components:
- EDTA Vacutainer (2ml)
Price: 3200.0 AED
Sample Condition:
Bone marrow / Peripheral blood (Transport immediately)
Report Delivery:
2-3 weeks
Method:
NGS (Next Generation Sequencing)
Test Type:
Genetics
Doctor:
General Physician
Test Department:
Pre Test Information
Pre Test Information:
The BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test can be done with a doctor’s prescription. Please note that prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Test Details
The BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test is a laboratory test used to detect mutations in the BCR-ABL1 gene. This gene is commonly found in chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL).
The BCR-ABL1 gene produces a protein called BCR-ABL1 kinase, which plays a crucial role in the development and progression of CML and ALL. Mutations in the BCR-ABL1 kinase domain can lead to resistance to targeted therapies such as tyrosine kinase inhibitors (TKIs).
The IRMA (Immune-Radiometric Assay) technique is used to analyze the BCR-ABL1 kinase domain mutations. This technique combines the use of antibodies and radioactive isotopes to detect and quantify specific mutations in the gene.
By analyzing the BCR-ABL1 kinase domain mutations, healthcare professionals can determine the presence of resistance mutations and tailor treatment options accordingly. This information helps in selecting the most appropriate TKI therapy for patients with CML or ALL, improving treatment outcomes and overall patient care.
| Test Name | BCR-ABL1 Kinase Domain Mutation Analysis IRMA Test |
|---|---|
| Components | EDTA Vacutainer (2ml) |
| Price | 3200.0 AED |
| Sample Condition | Bone marrow \/ Peripheral blood (Transport immediately) |
| Report Delivery | 2-3 weeks |
| Method | NGS |
| Test type | Genetics |
| Doctor | General Physician |
| Test Department: | |
| Pre Test Information | BCR-ABL1 Kinase Domain Mutation Analysis IRMA] can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
| Test Details |
BCR-ABL1 Kinase Domain Mutation Analysis [IRMA] is a laboratory test used to detect mutations in the BCR-ABL1 gene. BCR-ABL1 is a fusion gene that is commonly found in chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL). The BCR-ABL1 gene produces a protein called BCR-ABL1 kinase, which plays a crucial role in the development and progression of CML and ALL. Mutations in the BCR-ABL1 kinase domain can lead to resistance to targeted therapies such as tyrosine kinase inhibitors (TKIs). The IRMA (Immune-Radiometric Assay) technique is used to analyze the BCR-ABL1 kinase domain mutations. This technique combines the use of antibodies and radioactive isotopes to detect and quantify specific mutations in the gene. By analyzing the BCR-ABL1 kinase domain mutations, healthcare professionals can determine the presence of resistance mutations and tailor treatment options accordingly. This information helps in selecting the most appropriate TKI therapy for patients with CML or ALL, improving treatment outcomes and overall patient care. |
